X-154379517-G-A
Position:
Variant summary
Our verdict is Benign. Variant got -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS2
The ENST00000369842.9(EMD):c.33G>A(p.Glu11=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000197 in 1,169,888 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 5 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.000044 ( 0 hom., 1 hem., cov: 26)
Exomes 𝑓: 0.000017 ( 0 hom. 4 hem. )
Consequence
EMD
ENST00000369842.9 synonymous
ENST00000369842.9 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 2.06
Genes affected
EMD (HGNC:3331): (emerin) Emerin is a serine-rich nuclear membrane protein and a member of the nuclear lamina-associated protein family. It mediates membrane anchorage to the cytoskeleton. Dreifuss-Emery muscular dystrophy is an X-linked inherited degenerative myopathy resulting from mutation in the emerin gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -17 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.7).
BP6
Variant X-154379517-G-A is Benign according to our data. Variant chrX-154379517-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 1131752.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=2.06 with no splicing effect.
BS2
High Hemizygotes in GnomAdExome4 at 4 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
EMD | NM_000117.3 | c.33G>A | p.Glu11= | synonymous_variant | 1/6 | ENST00000369842.9 | NP_000108.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EMD | ENST00000369842.9 | c.33G>A | p.Glu11= | synonymous_variant | 1/6 | 1 | NM_000117.3 | ENSP00000358857 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000441 AC: 5AN: 113260Hom.: 0 Cov.: 26 AF XY: 0.0000282 AC XY: 1AN XY: 35430
GnomAD3 genomes
AF:
AC:
5
AN:
113260
Hom.:
Cov.:
26
AF XY:
AC XY:
1
AN XY:
35430
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000339 AC: 4AN: 118031Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 39965
GnomAD3 exomes
AF:
AC:
4
AN:
118031
Hom.:
AF XY:
AC XY:
0
AN XY:
39965
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000170 AC: 18AN: 1056628Hom.: 0 Cov.: 31 AF XY: 0.0000116 AC XY: 4AN XY: 345376
GnomAD4 exome
AF:
AC:
18
AN:
1056628
Hom.:
Cov.:
31
AF XY:
AC XY:
4
AN XY:
345376
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000441 AC: 5AN: 113260Hom.: 0 Cov.: 26 AF XY: 0.0000282 AC XY: 1AN XY: 35430
GnomAD4 genome
AF:
AC:
5
AN:
113260
Hom.:
Cov.:
26
AF XY:
AC XY:
1
AN XY:
35430
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Likely benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
X-linked Emery-Dreifuss muscular dystrophy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 20, 2023 | - - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 09, 2020 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at